View in EDS

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.

Saved in:
Bibliographic Details
Title: Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
Authors: Gregson SJ; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Pugh K; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Patel N; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Afif-Rider S; AstraZeneca, One Medimmune Way, Gaithersburg, Maryland., Vijayakrishnan B; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Santos K; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Riedl J; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Hutchinson I; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Kang GD; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Chooi KP; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Beard R; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Adams L; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Barry CS; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Ball K; AstraZeneca, Granta Park, Cambridge, United Kingdom., Masterson LA; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., McFarlane M; AstraZeneca, Granta Park, Cambridge, United Kingdom., Hartley JA; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom., Howard PW; TTD Chemistry, AstraZeneca, QMB Innovation Centre, 42 New Road, London, United Kingdom.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Sep 06; Vol. 21 (9), pp. 1439-1448.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-22-0145